ClinicalTrials.gg
RecruitingNCT06069518Updated Oct 21, 2026

Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis

An observational study in Kidney Disease, Chronic, Peritoneal Dialysis and Diabetes Mellitus Type 2, sponsored by Coordinación de Investigación en Salud, Mexico. Recruiting at 2 sites in Mexico. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Coordinación de Investigación en Salud, Mexico · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 21, 2026Now RecruitingFirst site in Mexico+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
110
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Renal Insufficiency, Chronic with a site in Mexico — 19 open to participants now, 31 under way, 14 of them phase 3. Renal Insufficiency, Chronic · Mexico.

Started
2024
with 8 others
Observational
6 of 83
5 open now
Primary completion
2027-03
later than 14 of 30 live
Registered
57th of 83
by date
Lead sponsor
4 of 83
Coordinación de Investigación en Salud, Mexico

Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, this one is one of 9 that started in 2024, is one of 6 observational ones, reaches primary completion later than 14 of the 30 other live ones, and was the 57th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

19 of the 83 studies in Renal Insufficiency, Chronic with a site in Mexico are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Renal Insufficiency, Chronic with a site in Mexico, or all of them as a file.
02

Study summary

Background: Patients with chronic kidney disease (CKD) caused by diabetes mellitus (DM) experience metabolic alterations characterized by elevated blood glucose levels and associated cardiovascular complications, which increase morbidity and mortality. Therefore, adequate metabolic control is necessary to reduce the incidence of these complications. This task is challenging without icodextrin because insulin adjustment is complicated by the additional glucose supplied through dialysis bags and absorbed through the peritoneum.

Under this premise, continuous glucose monitoring is important for assessing patients' metabolic status. This approach will provide clinically relevant data to improve care, minimize healthcare system expenses, and support decision-making regarding adjustments to dialysis treatment.

Objective: To use continuous glucose monitoring to determine whether the type, dose, route of administration, and timing of insulin application are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.

Material and Methods: This is a cross-sectional, non-interventional study involving adult patients with type 2 diabetes mellitus receiving automated peritoneal dialysis who exhibit high or high-average peritoneal transport characteristics.

The inclusion criteria are patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are insulin-dependent for metabolic control and have received peritoneal dialysis treatment for at least three months. The study will continuously evaluate patients' glycemic control, with automatic scanning and data recording every six hours during automated peritoneal dialysis infusion. According to the sample size calculation, 110 patients are required.

The Guardian 3 sensor will be placed subcutaneously in the upper posterior region of the patient's non-dominant arm using the One-press serter. This is a minimally invasive procedure that does not require surgical protocols. The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application.

The sensor has an approximate lifespan of seven days, corresponding to the duration of the enzymatic reaction that allows adequate measurement. Data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. At the end of this period, participants will be scheduled for placement of a second sensor to complete 14 days of follow-up.

On day seven, participants will undergo removal of the first sensor and placement of a new sensor to complete the 14-day follow-up period. On day 14, the total 24-hour peritoneal dialysis drainage volume will be collected to measure glucose, urea, and creatinine concentrations. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will be calculated. Dietary information will be collected to calculate caloric intake and meal timing. This information, together with subcutaneous insulin administration, will be recorded in the Guardian Connect application.

Statistical Analysis: The databases will be audited monthly through random sampling of blocks comprising 5% of their content. Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.

Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL. Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.

Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables. Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to detect differences between the adequate and inadequate glycemic control groups.

Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring. In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules. Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.

Read the detailed description

Background: Patients with chronic kidney disease (CKD) caused by diabetes mellitus (DM) experience metabolic alterations characterized by elevated blood glucose levels and associated cardiovascular complications, which increase morbidity and mortality. Therefore, adequate metabolic control is necessary to reduce the incidence of these complications. This task is challenging without icodextrin because insulin adjustment is complicated by the additional glucose supplied through dialysis bags and absorbed through the peritoneum.

Under this premise, continuous glucose monitoring is important for assessing patients' metabolic status. This approach will provide clinically relevant data to improve care, minimize healthcare system expenses, and support decision-making regarding adjustments to dialysis treatment.

Objective: To use continuous glucose monitoring to determine whether the type, dose, route of administration, and timing of insulin application are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.

Material and Methods: This is a cross-sectional, non-interventional study involving adult patients with type 2 diabetes mellitus receiving automated peritoneal dialysis who exhibit high or high-average peritoneal transport characteristics.

The inclusion criteria are patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are insulin-dependent for metabolic control and have received peritoneal dialysis treatment for at least three months. The study will continuously evaluate patients' glycemic control, with automatic scanning and data recording every six hours during automated peritoneal dialysis infusion. According to the sample size calculation, 110 patients are required.

The Guardian 3 sensor will be placed subcutaneously in the upper posterior region of the patient's non-dominant arm using the One-press serter. This is a minimally invasive procedure that does not require surgical protocols. The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application.

The sensor has an approximate lifespan of seven days, corresponding to the duration of the enzymatic reaction that allows adequate measurement. Data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. At the end of this period, participants will be scheduled for placement of a second sensor to complete 14 days of follow-up.

On day seven, participants will undergo removal of the first sensor and placement of a new sensor to complete the 14-day follow-up period. On day 14, the total 24-hour peritoneal dialysis drainage volume will be collected to measure glucose, urea, and creatinine concentrations. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will be calculated. Dietary information will be collected to calculate caloric intake and meal timing. This information, together with subcutaneous insulin administration, will be recorded in the Guardian Connect application.

Statistical Analysis: The databases will be audited monthly through random sampling of blocks comprising 5% of their content. Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.

Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL. Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.

Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables. Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to detect differences between the adequate and inadequate glycemic control groups.

Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring. In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules. Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.

Detailed Description JUSTIFICATION The high prevalence of patients with end-stage chronic kidney disease (CKD) treated with peritoneal dialysis (PD) and the predominance of diabetes mellitus (DM) as a cause of CKD make it necessary to establish documented guidelines for metabolic control in patients with DM receiving PD.

These guidelines should consider insulin dosage in relation to glucose intake from food and glucose absorption through the peritoneum. They should also consider meal schedules, infusion schedules for PD solutions with higher glucose concentrations, and the route of insulin administration, since the intraperitoneal route requires up to twice the dose administered subcutaneously.

To develop these guidelines, monitoring metabolic control using conventional tools, such as blood glucose measurements with a portable glucometer or glycated hemoglobin, is insufficient because these methods do not allow identification of the times of day when insulin should be administered to optimize its use. Continuous glucose monitoring is the only practical tool available for this purpose.

Recent reports identify CKD as the third chronic degenerative disease with the greatest financial impact on the Mexican Social Security Institute (IMSS). Together with diabetes mellitus and hypertension, CKD accounts for a substantial proportion of healthcare expenditure for patients with chronic diseases. Moreover, patients with DM represent more than half of those enrolled in dialysis programs.

In this context, metabolic control and fluid balance in patients with DM receiving PD represent both clinical and economic challenges.

RESEARCH QUESTION Is continuous glucose monitoring an effective tool for detecting the effects of insulin type, dose, route of administration, and timing on metabolic control in patients with diabetes receiving peritoneal dialysis? OBJECTIVES

General Objective:

To use continuous glucose monitoring to determine whether insulin type, dose, route of administration, and timing are associated with glucose patterns identified through continuous glucose monitoring, including the magnitude and duration of periods of hyperglycemia and hypoglycemia during 24-hour periods of interstitial glucose monitoring.

Specific Objectives:

  1. To identify insulin prescription patterns in patients with diabetes receiving PD, including insulin type, dose, administration schedule, and route of administration.
  2. To compare daily glucose concentration profiles measured by continuous glucose monitoring with fasting blood glucose concentrations and glycated hemoglobin percentages.
  3. To identify which insulin administration regimen is associated with shorter durations and lower magnitudes of hypoglycemia and hyperglycemia.
  4. To measure peritoneal glucose absorption and its relationship with glucose concentrations measured by continuous glucose monitoring.

MATERIALS AND METHODS

Design:

Cross-sectional, non-interventional study.

Population:

Adult patients with type 2 diabetes mellitus (DM2) and end-stage CKD receiving peritoneal dialysis.

Inclusion Criteria: Patients older than 40 years, of any sex, diagnosed with diabetic nephropathy, who are exclusively insulin-dependent for metabolic control and have received PD treatment for at least three months.

Non-Inclusion Criteria: Patients with positive serology for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus; acute complications; hospitalization for cardiovascular, metabolic, or infectious conditions during the month preceding study enrollment; cancer; pregnancy; or allergy.

OUTCOMES

Primary:

Average glucose concentration detected during 24-hour periods. Magnitude and duration of periods of hypoglycemia (\<70 mg/dL) and hyperglycemia (>180 mg/dL) recorded during 24-hour periods.

Secondary:

Necessary adjustments in insulin dosage during the monitoring period. PROCEDURES A member of the research team will invite patients who meet the eligibility criteria, as identified in PD consultation records, to participate in the study. Eligible patients will receive information about the study objectives and procedures.

For patients who agree to participate and sign the informed consent form, the initial interview will collect demographic information (sex, age, marital status, educational level, economic activity, and income), clinical information (underlying disease, disease duration, previous hospitalizations, and comorbidities), and laboratory information (complete blood count, basic biochemical parameters, inflammatory markers, mineral metabolism, nutritional parameters, and cardiovascular parameters) available in their medical records.

Information will be collected by nursing staff trained in clinical research procedures (monitors). The data collected will correspond to established dialysis adequacy criteria and are specified in the attached forms.

Participants will be scheduled for blood sample collection for biochemical analysis, including glucose, urea, creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, glycated hemoglobin, and C-reactive protein.

Participants will receive training in the use of the glucose monitor, which will be placed on the non-dominant arm. Once the monitor has been calibrated, participants will undergo monitoring for seven days. The first sensor will then be removed and replaced with a second sensor, completing a total follow-up period of 14 days.

The recorded data will be collected by the investigators and documented in forms designed for this purpose.

Patient training will consist of face-to-face theoretical and practical instruction. Proper performance of calibration procedures, glucose measurement consultation, and understanding of warning signals will be verified to ensure safe use of the monitoring device.

If glucose concentrations above 250 mg/dL are recorded at any time or persist for more than seven hours (30%) per day, participants will be referred for a detailed evaluation by their treating physician, who will have been previously informed of the inadequate metabolic control.

LABORATORY All biochemical and laboratory tests will be used for routine monitoring of patients receiving PD and will be performed at the affiliated hospital using standard automated techniques.

CONTINUOUS GLUCOSE MONITORING Guardian 3 sensor, Guardian Connect Transmitter Kit, and Guardian Connect System, consisting of the Guardian Connect transmitter, One-Press serter, Guardian Connect smartphone application (App), and standard printing equipment.

The sensor will be connected to the Guardian Connect transmitter for continuous communication with the Guardian Connect application. A smartphone is required for this purpose. If participants do not have a smartphone, one will be provided to enable appropriate follow-up.

After proper functioning has been verified through calibration supported by a glucometer and capillary blood glucose test strips, data will be transmitted every five minutes, 24 hours a day, for seven consecutive days. This period corresponds to the duration of the enzymatic reaction that allows adequate measurement.

At the end of the seven-day period, participants will be scheduled for placement of a second sensor to complete the 14-day follow-up period.

The information provided by the Guardian Connect system can be downloaded in Excel format and analyzed by the clinician through the CareLink website. The clinician will analyze trends, glucose concentration patterns, and major alerts indicating values outside the established range.

On day seven, participants will be scheduled for sensor removal, and the total 24-hour PD drainage volume will be collected for glucose, urea, and creatinine measurements. Peritoneal glucose absorption, the dialysate-to-plasma creatinine ratio (D/P creatinine), and Kt/V will also be calculated.

Dietary information will be obtained to calculate caloric intake and meal timing. Subcutaneous insulin administration will be recorded in the Guardian Connect application.

STATISTICAL PLAN The databases will be audited monthly through random sampling of blocks comprising 5% of their content.

Semiannual reports will be prepared to monitor the records collected and the outcomes obtained up to each reporting date. These reports will contain basic descriptive information, including measures of central tendency and dispersion, according to the characteristics of the variables.

Patients will be classified according to the percentage of time that glucose measurements remain within the predefined range of 70-180 mg/dL (24). Patients who spend at least 70% of the time within this range will be classified as having "Adequate" glycemic control, whereas those who do not reach this target will be classified as having "Not Adequate" glycemic control.

Results will be reported using measures of central tendency and dispersion appropriate to the characteristics of the variables.

Depending on the type of variable, the chi-square test, Student's t-test, or Mann-Whitney U test will be used to identify differences between the adequate and inadequate glycemic control groups.

Logistic regression analysis will be used to identify variables significantly associated with glycemic control within the recommended ranges, as assessed by continuous glucose monitoring.

In the first stage, each independent variable will be analyzed separately. In the second stage, multivariable analysis will be performed, considering insulin type, route of administration, dose, and administration schedules.

Potential confounding variables, including obesity, treatment adherence, diet, and physical activity prescribed by the treating physician, will also be included.

According to the protocol, the independent variables considered will be daily glucose absorption, insulin dose, administration timing in relation to food intake and the PD solutions used, and route of administration.

All analyses will be performed using SPSS version 24. Statistical significance will be established at p\<0.05.

SAMPLE SIZE The following assumptions were used to calculate the sample size:Statistical test: Logistic regression.

Dependent variable: Time spent with interstitial glucose concentrations within the target range, dichotomized as "Adequate" or "Not Adequate."Dominant covariate: Route of insulin administration, dichotomized as "Subcutaneous" or "Intraperitoneal."This variable is considered the most important covariate because it has been associated with better glycemic control in studies using individual blood glucose measurements obtained with a portable glucometer and glycated hemoglobin as indicators of metabolic control.α: 0.05.β: 0.9.OR: Risk of time outside the target range >85% (Intraperitoneal/Subcutaneous): 0.46/0.30.

Sample size: N = 110. ETHICAL ASPECTS The research will be conducted in accordance with the ethical principles and guidelines established in the Official Mexican Standard NOM-028-SSA2-1999, the General Health Law regarding research involving human participants, Articles 96 and 100 of Title V, and Technical Standard No. 313.

These regulations establish protections for participants' rights, dignity, well-being, and anonymity.

The following guidelines will be observed:An informed consent form is included and will be presented to participants by associated investigators duly accredited by the authorities of the participating medical units.

According to Article 21 of the Regulations of the General Health Law on Health Research (1984), informed consent requires that research participants or, when applicable, their legal representatives receive a clear and complete explanation that allows them to understand the relevant aspects of the study.

This research is considered minimal risk because it involves standard procedures used in routine physical examinations, diagnoses, or treatments. It also involves a device supported by published evidence that can provide additional parameters for metabolic control in patients with diabetes.

The use of this device does not involve venous bleeding or direct insulin administration, as the sensor is placed intradermally. The device may generate alerts that participants will be trained to recognize and manage appropriately.

According to clinical experience in the management of patients receiving PD, the observed glucose variations are within ranges that do not represent a risk to participants but may allow optimization of insulin administration.

If glucose concentrations above 250 mg/dL are recorded at any time or persist for more than seven hours (30%) per day, participants will be referred for a detailed evaluation by their treating physician, who will have been previously informed of the inadequate metabolic control.

The risk-benefit balance is considered favorable because the potential value of the information obtained is relevant and the study involves minimal risk.

None of the participating investigators has a conflict of interest regarding the use of the Guardian Connect device.

Samples will be handled by experienced personnel and prepared at each center, since only glycated hemoglobin measurements and clinical laboratory tests will be performed before participants' monthly consultations.

The research team acknowledges the General Health Law regarding research, as well as the applicable regulations and biosafety manuals. The following considerations will be observed:Installation of the Guardian Connect sensor requires trained personnel. The Latam Medtronic Academy provides training to minimize risks and ensure appropriate handling of installation materials.

No samples will be processed in a central laboratory because samples will be processed at each participating center to avoid transferring serum or plasma between centers.

The use of appropriate personal protective equipment is strongly recommended when installing sensors in patients receiving dialysis.

RESOURCES, FINANCING, AND FEASIBILITY The research team comprises a nephrologist with clinical experience in hospital-based patient care, a researcher specializing in nephrology, and two nurses. Electronic data collection will also be performed by trained personnel.

Additional anticipated costs are associated with the electronic devices required for continuous glucose monitoring, for which resources will be necessary.

The research group has demonstrated experience through various publications in the field of nephrology.

03

Conditions studied

  • Kidney Disease, Chronic
  • Peritoneal Dialysis
  • Diabetes Mellitus Type 2

Keywords

  • remote monitoring
  • Continuous glucose monitoring
  • peritoneal dialysis
  • diabetes mellitus
  • chronic kidney disease
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with type 2 diabetes mellitus and diabetic nephropathy receiving peritoneal dialysis for at least three months and requiring insulin for glycemic control. Trained research staff will identify eligible patients from peritoneal dialysis clinic records and invite them to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetic nephropathy.
  • Insulin-dependent diabetes mellitus requiring insulin for glycemic control.
  • At least three months of peritoneal dialysis treatment.

Exclusion criteria

Exclusion Criteria:

  • Positive serology for (HIV), virus (HBV), or virus (HCV).
  • Acute medical complications.
  • Hospitalization for cardiovascular, metabolic, or infectious conditions within the month preceding enrollment.
  • Cancer.
  • Pregnancy.
  • Allergy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Average glucose concentration detected in 24-hour periods.

    Amount of time that blood glucose is within the target range during and after dialysis fluid infusion. Measurement of time in which blood glucose levels are within the lower range of 70 mg/dL and an upper range of 180 mg/dL during and after the infusion of dialysis fluid.

    Time frame: 14 days of follow-up

Secondary outcomes

  1. Magnitude and duration of periods1s of hiccups (<70 mg/dl) and hyperglycemia (>180 mg/dl) recorded in 24-hour periods.

    Presence of hypoglycemia (glucose concentration less than 70 mg/dL) or hyperglycemia (glucose concentration greater than 180 mg/dL).

    Time frame: 14 days of follow-up

07

Study locations

2 of 2 sites recruiting
  • Hospital 1A Venados
    Mexico City, Mexico City 03300, Mexico
    Recruiting
  • Hospital General Regional 1 "Carlos Mc Gregor"
    Mexico City, Mexico City 3100, Mexico
    Recruiting
08

References and documents

Publications

  • Ng JKC, Ling J, Luk AOY, Lau ESH, Ma RCW, Li PKT, Szeto CC, Chan JCN, Chow E. Evaluation of a Fourth-Generation Subcutaneous Real-Time Continuous Glucose Monitor (CGM) in Individuals With Diabetes on Peritoneal Dialysis. Diabetes Care. 2023 Jun 1;46(6):1191-1195. doi: 10.2337/dc22-2348. PubMed 37043824 ↗
  • Bomholt T, Kofod D, Norgaard K, Rossing P, Feldt-Rasmussen B, Hornum M. Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis? Nephron. 2023;147(2):91-96. doi: 10.1159/000525676. Epub 2022 Jul 13. PubMed 35830847 ↗
  • Almalki MH, Altuwaijri MA, Almehthel MS, Sirrs SM, Singh RS. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Invest Med. 2012 Jun 1;35(3):E132-43. doi: 10.25011/cim.v35i3.16589. PubMed 22673316 ↗
  • Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocr Rev. 2020 Oct 1;41(5):756-74. doi: 10.1210/endrev/bnaa017. PubMed 32455432 ↗
  • Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant. 2005 Sep;20(9):1848-53. doi: 10.1093/ndt/gfh946. Epub 2005 Jun 21. PubMed 15972319 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 33 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Nov 2023 → Jun 2024, primary completion Jun 2024 → Mar 2027 and completion Nov 2024 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 5, 2023
StartActual
Jun 1, 2024was Nov 2023
Primary completionEst.
Mar 31, 2027was Jun 2024
CompletionEst.
Jun 30, 2027was Nov 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
2 sites added — first site in Mexico
Show 2 added (2 Mexico)
  • Hospital 1A Venados · Mexico City, Mexico
  • Hospital General Regional 1 "Carlos Mc Gregor" · Mexico City, Mexico
Oct 21, 2026
Start date
Nov 1, 2023→Jun 1, 2024 (actual)
Oct 21, 2026
Primary completion
Jun 1, 2024→Mar 31, 2027
Oct 21, 2026
Study completion
Nov 1, 2024→Jun 30, 2027
Oct 21, 2026
Eligibility
3 inclusion criteria added; 6 exclusion criteria added; 2 criteria removed
What changed in the criteria
  • RemovedInclusion Criteria: Participants over 40 years of age, of any sex, diagnosed with Diabetic Nephropathy, and who are exclusively insulin-dependent for metabolic control, with at least three months of PD treatment.
  • RemovedExclusion Criteria: Patients with positive serology for HIV and hepatitis B and C, acute complications, and hospitalization for cardiovascular, metabolic or infectious disease in the month prior to inclusion in the study, cancer, pregnancy, or allergy.
Inclusion criteria
  • AddedDiagnosis of diabetic nephropathy.
  • AddedInsulin-dependent diabetes mellitus requiring insulin for glycemic control.
  • AddedAt least three months of peritoneal dialysis treatment.
Exclusion criteria
  • AddedPositive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  • AddedAcute medical complications.
  • AddedHospitalization for cardiovascular, metabolic, or infectious conditions within the month preceding enrollment.
  • AddedCancer.
  • AddedPregnancy.
  • AddedAllergy.
Oct 21, 2026
Contact
Study contact changed: a•••@hotmail.com · •••3541→a•••@hotmail.com · •••3541. See the current contact
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in Mexico
    Show 2 added (2 Mexico)
    • Hospital 1A Venados · Mexico City, Mexico
    • Hospital General Regional 1 "Carlos Mc Gregor" · Mexico City, Mexico
    Start date Nov 1, 2023→Jun 1, 2024 (now actual)
    Primary completion Jun 1, 2024→Mar 31, 2027
    Study completion Nov 1, 2024→Jun 30, 2027
    Eligibility 3 inclusion criteria added; 6 exclusion criteria added; 2 criteria removed
    What changed in the criteria
    • RemovedInclusion Criteria: Participants over 40 years of age, of any sex, diagnosed with Diabetic Nephropathy, and who are exclusively insulin-dependent for metabolic control, with at least three months of PD treatment.
    • RemovedExclusion Criteria: Patients with positive serology for HIV and hepatitis B and C, acute complications, and hospitalization for cardiovascular, metabolic or infectious disease in the month prior to inclusion in the study, cancer, pregnancy, or allergy.
    Inclusion criteria
    • AddedDiagnosis of diabetic nephropathy.
    • AddedInsulin-dependent diabetes mellitus requiring insulin for glycemic control.
    • AddedAt least three months of peritoneal dialysis treatment.
    Exclusion criteria
    • AddedPositive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
    • AddedAcute medical complications.
    • AddedHospitalization for cardiovascular, metabolic, or infectious conditions within the month preceding enrollment.
    • AddedCancer.
    • AddedPregnancy.
    • AddedAllergy.
    Contact Study contact changed: a•••@hotmail.com · •••3541→a•••@hotmail.com · •••3541. See the current contact
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06069518
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Jun 1, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Miguel Angel Cuevas Budhart A Cuevas-Budhart, MSc, PhD
Contact
angel_budhart@hotmail.com
+525559443541
José Ramón Paniagua Sierra. R Paniagua,, PhD
study director · Unidad de Investigación Médica en Enfermedades Nefrológicas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion